CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2017--
AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle, M.D.,
Chief Medical Officer, will present at the 19th Annual BIO CEO &
Investor Conference on Monday, February 13, 2017 at 8:30 AM E.T. at the
Waldorf Astoria Hotel in New York City.
A live webcast can be accessed by visiting the investors section of the
Company’s website at www.aveooncology.com.
A replay of the webcast will be archived for 30 days following the
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to
advancing a broad portfolio of targeted therapeutics for oncology and
other areas of unmet medical need. The company is focused on developing
and commercializing its lead candidate tivozanib, a potent, selective,
long half-life inhibitor of vascular endothelial growth factor 1, 2 and
3 receptors, in North America as a treatment for Renal Cell Carcinoma
and other cancers. AVEO is leveraging multiple partnerships to develop
and commercialize tivozanib in non-oncologic indications worldwide and
oncology indications outside of North America, as well as to progress
its pipeline of novel therapeutic candidates in cancer and cachexia
(wasting syndrome). For more information, please visit the company’s
website at www.aveooncology.com.
AVEO Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO that
involve substantial risks and uncertainties. All statements, other than
statements of historical fact, contained in this press release are
forward-looking statements. Actual results or events could differ
materially due to a number of important factors, including risks
discussed in the section titled “Risk Factors” in AVEO’s most recent
Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its
other filings with the SEC. The forward-looking statements in this press
release represent AVEO’s views as of the date of this press release.
AVEO anticipates that subsequent events and developments may cause its
views to change. While AVEO may elect to update these forward-looking
statements at some point in the future, it specifically disclaims any
obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing AVEO’s views as of any date
other than the date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170206005314/en/
Source: AVEO Oncology
David Pitts, 212-600-1902